On Saturday, 21 November, the Movember Team will be at the Market to educate, promote the cause and fundraise for prostrate cancer research. These group of guys are actually prostate cancer researchers from the Australian Prostate Cancer Research Centre-QLD (http://www.australianprostatecentre.org) based at the PA Hospital. They’ll be at the Markets to answer any questions people might have about prostate cancer and/or mens health in general. Movember is an annual, month-long celebration of the moustache, highlighting men’s health issues, specifically prostate cancer and depression in men. This November be a Mo Bro or Mo Sista.
The Australian Prostate Cancer Research Centre – Queensland is a dedicated, disease-specific national prostate cancer research centre based in Brisbane.
The APCRC – Q was established in 2008 as a joint initiative between Queensland University of Technology’s Institute of Health and Biomedical Innovation and the Princess Alexandra Hospital. Led by Professor Colleen Nelson, APCRC-Q is modelled on the successful Vancouver Prostate Centre at Vancouver General Hospital in Canada, of which Prof Nelson is a co-founder. In early 2009, we were awarded a $7.5 million Commonwealth grant from the Australian Government Department of Health and Ageing. Later that year, we launched the Multidisciplinary Team Clinic (MDT) for Advanced Prostate Cancer. We were awarded additional funding of $6.2 million from the Australian Department of Health and Ageing in May 2013.
APCRC-Q will improve the clinical management of prostate cancer by developing better diagnosis and treatment strategies for Australian men.
With more than 65 academic and clinical faculty, researchers and trainees, APCRC-Q spans the full spectrum of prostate cancer research – including discovery, diagnostic and therapeutic development, and health services – through the dedication and passion of a large, coordinated, multidisciplinary biomedical, clinical and public health research team.
The mission of its dedicated transdisciplinary team is to drive the development and translation of new therapeutics and biomarkers for prostate cancer through integrated and consolidated resources and expertise, national and international partnerships, and leveraged funding.
For more information visit: